Toward selective anticancer metallodrugs

Abstract

The field of transition-metal based chemotherapeutics are

dominated by derivatives of cisplatin, but a major downside of these platinum

based chemotherapeutics is their lack of selectivity that leads to

undesirable side effects. In this work we present alternative strategies such as light-activation with different transition-metals such as ruthenium and palladium that have the potential to be more selective than cisplatin type of drugs.